-
1.发明公开METHOD OF DECREASING CYTOTOXIC SIDE-EFFECTS AND IMPROVING EFFICACY OF IMMUNOCONJUGATES 审中-公开法降低细胞毒副作用及免疫偶联物的有效性
公开(公告)号：EP2238169A1
公开(公告)日：2010-10-13
申请号：EP08864283.0
申请日：2008-12-23
申请人： Biotest AG , Immunogen, Inc.
发明人： SCHULZ, Gregor , OSTERROTH, Frank , AIGNER, Silke , UHEREK, Christoph , BRUECHER, Christoph , ZENG, Steffen , DAELKEN, Benjamin , RUEHLE, Markus , KRAUS, Elmar
CPC分类号： C07K16/2896 , A61K39/39558 , A61K47/48561 , A61K47/48569 , A61K47/48723 , A61K47/6849 , A61K47/6851 , A61K47/6891 , A61K2039/505 , A61K2300/00 , B82Y5/00 , C07K2317/24 , C07K2317/34
摘要： Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and kits allow appropriate sequestration of non-target cells while maintaining a high degree of effectiveness of the immunoconjugates against target cells.
-
公开(公告)号：EP2427216B1
公开(公告)日：2019-02-20
申请号：EP10718581.1
申请日：2010-05-05
申请人： Biotest AG , ImmunoGen, Inc.
-
3.发明授权METHODS AND AGENTS FOR IMPROVING TARGETING OF CD138 EXPRESSING TUMOR CELLS 有权方式和途径改进ABZIELUNG ON CD138表达的肿瘤细胞
公开(公告)号：EP2240516B1
公开(公告)日：2015-07-08
申请号：EP08865592.3
申请日：2008-12-23
发明人： DAELKEN, Benjamin , UHEREK, Christoph , ANDERSON, Kenneth , HIDESHIMA, Teru , BRUECHER, Christoph , OSTERROTH, Frank , AIGNER, Silke , GERMER, Matthias
IPC分类号： C07K16/28 , C07K16/30 , A61P35/00 , A61K47/48 , A61K39/395
CPC分类号： A61K47/48561 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6867 , A61K2039/505 , C07K16/2896 , C07K2317/34 , C07K2317/73 , C07K2317/92
-
公开(公告)号：EP2242772A1
公开(公告)日：2010-10-27
申请号：EP08865838.0
申请日：2008-12-23
申请人： Biotest AG , Immunogen, Inc.
发明人： KRAUS, Elmar , BRUECHER, Christoph , DAELKEN, Benjamin , ZENG, Steffen , OSTERROTH, Frank , UHEREK, Christoph , AIGNER, Silke , GERMER, Matthias
IPC分类号： C07K16/28 , C07K16/30 , A61P35/00 , A61K47/48 , A61K39/395
CPC分类号： C07K16/2896 , A61K45/06 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6867 , A61K47/6877 , C07K2317/24 , C07K2317/565 , C07K2317/92
摘要： Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.
-
5.发明授权IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF 有权AUF CD138 ZIELENDE IMMUNKONJUGATE UND ANWENDUNGEN DAVON
公开(公告)号：EP2242772B1
公开(公告)日：2014-11-26
申请号：EP08865838.0
申请日：2008-12-23
申请人： Biotest AG , Immunogen, Inc.
发明人： KRAUS, Elmar , BRUECHER, Christoph , DAELKEN, Benjamin , ZENG, Steffen , OSTERROTH, Frank , UHEREK, Christoph , AIGNER, Silke , GERMER, Matthias , SCHULZ, Gregor , HAEDER, Thomas
IPC分类号： C07K16/28 , C07K16/30 , A61P35/00 , A61K47/48 , A61K39/395
CPC分类号： C07K16/2896 , A61K45/06 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6867 , A61K47/6877 , C07K2317/24 , C07K2317/565 , C07K2317/92
-
公开(公告)号：EP2427216A2
公开(公告)日：2012-03-14
申请号：EP10718581.1
申请日：2010-05-05
申请人： Biotest AG , ImmunoGen, Inc.
发明人： OSTERROTH, Frank , UHEREK, Christoph , BRUECHER, Christoph , DAELKEN, Benjamin , ENGLING, André , HAEDER, Thomas , WARTENBERG-DEMAND, Andrea , NIEMANN, Gabriele , ZUBER, Chantal , CZELOTH, Niklas , AIGNER, Silke , ZENG, Steffen , SCHULZ, Gregor
CPC分类号： A61K47/6425 , A61K47/66 , A61K47/6851 , B82Y5/00
摘要： Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.
-
公开(公告)号：EP2788030B1
公开(公告)日：2018-06-20
申请号：EP12798723.8
申请日：2012-12-07
申请人： Biotest AG , ImmunoGen, Inc.
发明人： SCHULZ, Gregor , OSTERROTH, Frank , HAEDER, Thomas , BRUECHER, Christoph , NIEMANN, Gabriele , ENGLING, Andre , UHEREK, Christoph , DAELKEN, Benjamin , WARTENBERG-DEMAND, Andrea , ZUBER, Chantal , GUTSCHER, Marcus , BERNOESTER, Katrin , KOENIG, Martin
CPC分类号： A61K39/39558 , A61K47/6809 , A61K47/6851
摘要： Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.
-
公开(公告)号：EP2788030A1
公开(公告)日：2014-10-15
申请号：EP12798723.8
申请日：2012-12-07
申请人： Biotest AG , ImmunoGen, Inc.
发明人： SCHULZ, Gregor , OSTERROTH, Frank , HAEDER, Thomas , BRUECHER, Christoph , NIEMANN, Gabriele , ENGLING, Andre , UHEREK, Christoph , DAELKEN, Benjamin , WARTENBERG-DEMAND, Andrea , ZUBER, Chantal , GUTSCHER, Marcus , BERNOESTER, Katrin , KOENIG, Martin
CPC分类号： A61K39/39558 , A61K47/6809 , A61K47/6851
摘要： Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.
摘要翻译： 公开了用于治疗与多剂量方案中表达CD138的靶细胞相关的疾病的方法和组合物。 包含靶向CD138表达细胞的工程化靶向抗体和效应分子的免疫缀合物以多剂量方案给药。 多剂量方案包含至少两个剂量，并且在活性治疗周期内施用的总剂量是聚集体最大可耐受剂量（AMTD）或AMTD的一部分。 当免疫缀合物以单一剂量施用时，AMTD和/或所述级分超过导致剂量限制性毒性（DLT）的剂量和/或超过最大耐受剂量（MTD），包括作为所述多发单剂量方案的一部分 积极的治疗周期。
-
9.发明公开METHODS AND AGENTS FOR IMPROVING TARGETING OF CD138 EXPRESSING TUMOR CELLS 有权方式和途径改进ABZIELUNG ON CD138表达的肿瘤细胞
公开(公告)号：EP2240516A1
公开(公告)日：2010-10-20
申请号：EP08865592.3
申请日：2008-12-23
发明人： DAELKEN, Benjamin , UHEREK, Christoph , ANDERSON, Kenneth , HIDESHIMA, Teru , BRUECHER, Christoph
IPC分类号： C07K16/28 , C07K16/30 , A61P35/00 , A61K47/48 , A61K39/395
CPC分类号： A61K47/48561 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6867 , A61K2039/505 , C07K16/2896 , C07K2317/34 , C07K2317/73 , C07K2317/92
摘要： Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This deminished adhesion renders the tumor cells not only susceptible to the immunconjugate, but also to other agents, in particular cytotoxic agents.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.027 秒)
